Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials /

OBJECTIVE: Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double-blind, placebo-controlled trials, the EMBODY 1 and EMBODY...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Clowse Megan E. B.
Wallace Daniel J.
Furie Richard A.
Petri Michelle A.
Pike Marilyn C.
Leszczynski Piotr
Neuwelt C. Michael
Hobbs Kathryn
Keiserman Mauro
Duca Liliana
Kalunian Kenneth C.
EMBODY Investigator Group
Gasztonyi Beáta
Géher Pál
Kemény Lajos
Kiss Emese
Kovács László
Szűcs Gabriella
et al
Dokumentumtípus: Cikk
Megjelent: John Wiley and Sons, Inc. 2017
Sorozat:ARTHRITIS & RHEUMATOLOGY 69 No. 2
doi:10.1002/art.39856

mtmt:3217512
Online Access:http://publicatio.bibl.u-szeged.hu/12731

Hasonló tételek